Featured Research

from universities, journals, and other organizations

Old drug offers new hope against rare, deadly childhood disease​

Date:
April 2, 2013
Source:
Washington University in St. Louis
Summary:
Washington University School of Medicine in St. Louis is playing a leading role in one of the National Institutes of Health’s (NIH) first clinical trials to improve treatments for rare and neglected diseases. In this case, the disease is Niemann-Pick Type C, a disorder that causes excess cholesterol to accumulate in the brain, liver and spleen. It affects about 500 children worldwide, leads to neurodegeneration, and usually causes death in the first two decades of life. The compound to be tested is called cyclodextrin, a cyclic sugar long used as an ingredient in other drugs.

Cyclodextrin molecule.
Credit: Daniel S. Ory, MD

Washington University School of Medicine in St. Louis is playing a leading role in one of the National Institutes of Health's (NIH) first clinical trials to improve treatments for rare and neglected diseases.

In this case, the disease is Niemann-Pick Type C, a disorder that causes excess cholesterol to accumulate in the brain, liver and spleen. It affects about 500 children worldwide, leads to neurodegeneration, and usually causes death in the first two decades of life. The compound to be tested is called cyclodextrin, a cyclic sugar long used as an ingredient in other drugs.

"You probably ingest cyclodextrins all the time and don't realize it," says Daniel S. Ory, MD, professor of medicine and of cell biology and physiology. "It's used as a carrier in many drug formulations because of its ability to solubilize drugs that don't dissolve well in water."

According to Ory, the trial will test a new application of a compound already approved by the U.S. Food and Drug Administration to help with drug delivery. Cyclodextrin has just never been used in the high doses that successfully treated animal models of Niemann-Pick Type C (NPC).

"We've been studying this disease for many years, and we began looking at this drug in earnest about five years ago," Ory says. "In animal models of NPC, we see significant benefit in both neurological function and survival. It's superior to all other compounds we have tested in the animal models."

The nine patients they are enrolling in this Phase 1 trial are being treated at the NIH Clinical Center in Bethesda, MD. In St. Louis, Ory and his colleagues are tracking their progress with new techniques developed at Washington University. This includes novel methods to monitor whether the drug is having an effect, both in the cerebrospinal fluid and the blood.

"The patients' samples are being shipped to us, and we are using our facilities to monitor the progress of the patients and report the results back to the NIH," Ory says. "Based on our results, the NIH team will make decisions about whether to move forward with escalating the dose."

The disorder causes cholesterol to accumulate inside compartments in cells called lysosomes. The buildup leads to dysfunction and loss of large neurons in the central nervous system. Based on successes in animal studies, Ory says cyclodextrin delivered directly to the brain acts as a key to unlock the trapped cholesterol and allows it to redistribute in the cell where it can be properly metabolized and removed.

In addition to new ways to monitor the effects of cyclodextrin, Ory and his colleagues have developed better ways to diagnose the disease in the first place. He hopes to adapt his group's diagnostic techniques for newborn screening purposes. According to Ory, the disease is under-diagnosed because the earliest symptoms are not specific and are easily overlooked.

"At first, a child might display mild cognitive impairment, perhaps be a little bit clumsy," Ory says. "Eventually, the child will get to a tipping point and begin a slide toward progressive neurological disability."

"But if we can diagnose at birth, and we have treatments like the one we are testing, we could intervene before the onset of neurological symptoms. That would change the natural history of the disease -- taking kids who would have died in childhood and helping them live to adulthood."

While this Phase 1 trial will test safety, Ory and his collaborators at the NIH and other institutions are developing plans for a Phase 2/3 trial to be headquartered at Washington University that will test more patients and determine the effectiveness of the treatment.

"This is a great example of a novel partnership between the NIH, academic researchers, industry, patients and family organizations that is having success in addressing a group of patients with unmet needs," Ory says. "We want other researchers to look at this model and think about applying it to other disorders."

In addition to Washington University, the collaborating institutions include the National Center for Advancing Translational Sciences; Eunice Kennedy Shriver National Institute of Child Health and Human Development; the NIH's Therapeutics for Rare and Neglected Diseases program; the Network for Excellence in Neuroscience Clinical Trials; National Institute of Neurological Disorders and Stroke; National Human Genome Research Institute; Johnson and Johnson Pharmaceutical Research & Development; Albert Einstein School of Medicine in New York City; and the University of Pennsylvania, Philadelphia.

Other organizations providing support include the Ara Parshegian Medical Research Foundation, the International Niemann Pick Disease Alliance, the National Niemann Pick Disease Foundation, and Support of Accelerated Research For Niemann-Pick Type C.


Story Source:

The above story is based on materials provided by Washington University in St. Louis. The original article was written by Julia Evangelou Strait. Note: Materials may be edited for content and length.


Cite This Page:

Washington University in St. Louis. "Old drug offers new hope against rare, deadly childhood disease​." ScienceDaily. ScienceDaily, 2 April 2013. <www.sciencedaily.com/releases/2013/04/130402171110.htm>.
Washington University in St. Louis. (2013, April 2). Old drug offers new hope against rare, deadly childhood disease​. ScienceDaily. Retrieved October 2, 2014 from www.sciencedaily.com/releases/2013/04/130402171110.htm
Washington University in St. Louis. "Old drug offers new hope against rare, deadly childhood disease​." ScienceDaily. www.sciencedaily.com/releases/2013/04/130402171110.htm (accessed October 2, 2014).

Share This



More Health & Medicine News

Thursday, October 2, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Pregnancy Spacing Could Have Big Impact On Autism Risks

Pregnancy Spacing Could Have Big Impact On Autism Risks

Newsy (Oct. 1, 2014) A new study says children born less than one year and more than five years after a sibling can have an increased risk for autism. Video provided by Newsy
Powered by NewsLook.com
Robotic Hair Restoration

Robotic Hair Restoration

Ivanhoe (Oct. 1, 2014) A new robotic procedure is changing the way we transplant hair. The ARTAS robot leaves no linear scarring and provides more natural results. Video provided by Ivanhoe
Powered by NewsLook.com
Insertable Cardiac Monitor

Insertable Cardiac Monitor

Ivanhoe (Oct. 1, 2014) A heart monitor the size of a paperclip that can save your life. The “Reveal Linq” allows a doctor to monitor patients with A-Fib on a continuous basis for up to 3 years! Video provided by Ivanhoe
Powered by NewsLook.com
Attacking Superbugs

Attacking Superbugs

Ivanhoe (Oct. 1, 2014) Two weapons hospitals can use to attack superbugs. Scientists in Ireland created a new gel resistant to superbugs, and a robot that can disinfect a room in minutes. Video provided by Ivanhoe
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins